Literature DB >> 28667191

Providing active antenatal care depends on the place of birth for extremely preterm births: the EPIPAGE 2 cohort study.

Caroline Diguisto1,2,3, François Goffinet1,4, Elsa Lorthe1,5, Gilles Kayem1,5,6, Jean-Christophe Roze7, Pascal Boileau8, Babak Khoshnood1, Valérie Benhammou1, Bruno Langer9, Loic Sentilhes10, Damien Subtil11, Elie Azria1,12, Monique Kaminski1, Pierre-Yves Ancel1,13, Laurence Foix-L'Hélias1,5,14.   

Abstract

Survival rates of infants born before 25 weeks of gestation are low in France and have not improved over the past decade. Active perinatal care increases these infants' likelihood of survival.
OBJECTIVE: Our aim was to identify factors associated with active antenatal care, which is the first step of proactive perinatal care in extremely preterm births.
METHODS: The population included 1020 singleton births between 220/6 and 260/6 weeks of gestation enrolled in the Etude Epidémiologique sur les Petits Ages Gestationnels 2 study, a French national population-based cohort of very preterm infants born in 2011. The main outcome was 'active antenatal care' defined as the administration of either corticosteroids or magnesium sulfate or delivery by caesarean section for fetal rescue. A multivariable analysis was performed using a two-level multilevel model taking into account the maternity unit of delivery to estimate the adjusted ORs (aORs) of receiving active antenatal care associated with maternal, obstetric and place of birth characteristics.
RESULTS: Among the population of extremely preterm births, 42% received active antenatal care. After standardisation for gestational age, regional rates of active antenatal care varied between 22% (95% CI 5% to 38%) and 61% (95% CI 44% to 78%). Despite adjustment for individual and organisational characteristics, active antenatal care varied significantly between maternity units (p=0.03). Rates of active antenatal care increased with gestational age with an aOR of 6.46 (95% CI 3.40 to 12.27) and 10.09 (95% CI 5.26 to 19.36) for infants born at 25 and 26 weeks' gestation compared with those born at 24 weeks. No other individual characteristic was associated with active antenatal care.
CONCLUSION: Even after standardisation for gestational age, active antenatal care in France for extremely preterm births varies widely with place of birth. The dependence of life and death decisions on place of birth raises serious ethical questions. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Extreme preterm birth; active antenatal care

Mesh:

Year:  2017        PMID: 28667191     DOI: 10.1136/archdischild-2016-312322

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  3 in total

1.  Healthcare organizational factors associated with delayed therapeutic hypothermia in neonatal hypoxic-ischemic encephalopathy: the LyTONEPAL cohort.

Authors:  Véronique Pierrat; Anne Ego; Jonathan Beck; Thierry Debillon; Isabelle Guellec; Antoine Vilotitch; Gauthier Loron; Nathalie Bednarek; Pierre-Yves Ancel
Journal:  Eur J Pediatr       Date:  2022-10-21       Impact factor: 3.860

2.  Intensity of perinatal care, extreme prematurity and sensorimotor outcome at 2 years corrected age: evidence from the EPIPAGE-2 cohort study.

Authors:  Andrei S Morgan; Laurence Foix L'Helias; Caroline Diguisto; Laetitia Marchand-Martin; Monique Kaminski; Babak Khoshnood; Jennifer Zeitlin; Gérard Bréart; Xavier Durrmeyer; François Goffinet; Pierre-Yves Ancel
Journal:  BMC Med       Date:  2018-12-05       Impact factor: 8.775

3.  Cohort Profile: the Etude Epidémiologique sur les Petits Ages Gestationnels-2 (EPIPAGE-2) preterm birth cohort.

Authors:  Elsa Lorthe; Valérie Benhammou; Laetitia Marchand-Martin; Véronique Pierrat; Cécile Lebeaux; Mélanie Durox; François Goffinet; Monique Kaminski; Pierre-Yves Ancel
Journal:  Int J Epidemiol       Date:  2021-11-10       Impact factor: 7.196

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.